Abstract
Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 399-418 |
| Number of pages | 20 |
| Journal | Immunotherapy |
| Volume | 2 |
| Issue number | 3 |
| DOIs | |
| State | Published - May 2010 |
Fingerprint
Keywords
- Adoptive immunotherapy
- Antigen-presenting cell
- Graft-versus-host disease
- Graft-versus-leukemia
- Graft-versus-tumor
- Hematopoietic stem cell transplantation
- Myeloablative conditioning
- Natural killer cell
- Nonmyeloablative conditioning
- Regulatory T cell
ASJC Scopus subject areas
- Immunology and Allergy
- Oncology
- Immunology
Cite this
Immunotherapy following hematopoietic stem cell transplantation : Potential for synergistic effects. / Bouchlaka, Myriam N.; Redelman, Doug; Murphy, William J.
In: Immunotherapy, Vol. 2, No. 3, 05.2010, p. 399-418.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunotherapy following hematopoietic stem cell transplantation
T2 - Potential for synergistic effects
AU - Bouchlaka, Myriam N.
AU - Redelman, Doug
AU - Murphy, William J
PY - 2010/5
Y1 - 2010/5
N2 - Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.
AB - Hematopoietic stem cell transplantation (HSCT) is a particularly important treatment for hematologic malignancies. Unfortunately, following allogeneic HSCT, graft-versus-host disease, immunosuppression and susceptibility to opportunistic infections remain among the most substantial problems restricting the efficacy and use of this procedure, particularly for cancer. Adoptive immunotherapy and/or manipulation of the graft offer ways to attack residual cancer as well as other transplant-related complications. Recent exciting discoveries have demonstrated that HSCT could be expanded to solid tissue cancers with profound effects on the effectiveness of adoptive immunotherapy. This review will provide a background regarding HSCT, discuss the complications that make it such a complex treatment procedure following up with current immunotherapeutic strategies and discuss emerging approaches in applying immunotherapy in HSCT for cancer.
KW - Adoptive immunotherapy
KW - Antigen-presenting cell
KW - Graft-versus-host disease
KW - Graft-versus-leukemia
KW - Graft-versus-tumor
KW - Hematopoietic stem cell transplantation
KW - Myeloablative conditioning
KW - Natural killer cell
KW - Nonmyeloablative conditioning
KW - Regulatory T cell
UR - http://www.scopus.com/inward/record.url?scp=77953435075&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77953435075&partnerID=8YFLogxK
U2 - 10.2217/imt.10.20
DO - 10.2217/imt.10.20
M3 - Article
C2 - 20635904
AN - SCOPUS:77953435075
VL - 2
SP - 399
EP - 418
JO - Immunotherapy
JF - Immunotherapy
SN - 1750-743X
IS - 3
ER -